Human bladder cancer vidicetumab drug-resistant cell strain as well as construction method and application thereof
By constructing the RC48 drug-resistant cell line T24-RC48 on the bladder cancer cell line T24, the problem of bladder cancer resistance to RC48 drugs was solved, and an effective cellular model for studying drug resistance mechanisms and developing reverse drugs was provided.
Patent Information
- Application Number
- CN202510194891.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-21
- Publication Date
- 2025-06-27
AI Technical Summary
Bladder cancer has a drug resistance to vedicitumab (RC48) drugs, resulting in poor treatment results. The existing technology has failed to effectively explore drug resistance mechanisms and overcome drug resistance problems.
By using the method of continuously induction and gradual increase in drug concentration and treatment time on human bladder transition cell carcinoma T24 cells, the human bladder transition cell carcinoma cell line T24-RC48 that is resistant to RC48 was successfully constructed.
The constructed T24-RC48 cell line can still grow stably in a high concentration of RC48 environment, with a drug resistance index of 9.8, providing an effective cell model for studying the mechanism of bladder cancer resistance and developing reversal drugs.
Smart Images

Figure CN120210124A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a human bladder cancer vedicizumab-resistant cell line, a construction method thereof, and related applications. Background Art
[0002] Bladder cancer (BLCA) is the most common malignant tumor in the urinary system. In recent years, there are about 550,000 new cases worldwide each year, with a mortality rate of up to 33%. In 2022, there will be more than 610,000 new cases worldwide, ranking ninth among cancers, of which more than 220,000 people will die from it. Taking into account the assumption of the prevalence of smoking in the short term, it is estimated that by 2040, the number of deaths due to BLCA in men may be between 163,000 and 245,000 (the mortality rate decreases at a rate of -3%, -2% and -1% per year), and the number of deaths in women may be between 119,000 and 176,000 (the mortality rate increases at a rate of 1%, 2% and 3% per year). At present, the clinical drug treatment of BLCA is mainly based on traditional chemotherapy and immunotherapy. Although surgery and chemotherapy can improve the survival rate of patients, the prognosis is still not ideal: the recurrence rate and migration rate of bladder cancer are as high as 20%. About 50% of patients who undergo radical cystectomy have recurrence or migration after surgery, most of which are distant migration. The 5-year survival rate of patients diagnosed with metastatic disease is only 5%, and the total survival time is 9 to 15 months. In China, the number of bladder cancer cases in 2022 is 92,883, accounting for 15% of new cases worldwide; the incidence rate is 1.9%, ranking 11th among all cancers; the number of deaths is 41,364, accounting for 19% of global deaths; the mortality rate is 1.6%, ranking 12th among all cancers. Therefore, exploring the mechanism of bladder cancer resistance, overcoming the problem of drug resistance, and improving drug efficacy have become key issues that need to be urgently addressed in the treatment of bladder cancer.
[0003] Disitamab vedotin (trade name: Aidixi®, research code: RC48) is the first original antibody-drug conjugate (ADC) drug developed in China by Rongchang Biologics. It is a novel anti-HER2 ADC that contains a novel monoclonal antibody capable of binding to different epitopes of human epidermal growth factor receptor-2 (HER2) on target tumor cells and showing high affinity, a linker, and the cytotoxic drug monomethyl auristatin E (MMAE) (a potent microtubule-binding agent with a half-maximal inhibitory concentration (IC50) in the sub-nanomolar range, used as a toxin payload). It can target the HER2 protein on the tumor surface, precisely recognize and penetrate the cell membrane, thereby killing cancer cells with small molecule cytotoxic drugs, and is used to treat patients with locally advanced or metastatic gastric cancer and urothelial carcinoma. Once released, MMAE also has the ability to kill adjacent tumor cells (regardless of HER2 expression), which is called the bystander effect. Studies have found that ADCs with higher membrane permeability payloads (such as MMAE) have a stronger bystander effect compared to ADCs with lower membrane permeability payloads, indicating that disitamab vedotin has higher anti-tumor potential.
[0004] Despite numerous breakthroughs, ADC drugs almost always encounter intrinsic and acquired resistance in most tumors. The resistance mechanism of RC48 is still unclear at present. Therefore, establishing a RC48-resistant cell line for bladder cancer to explore the resistance mechanism of bladder cancer, overcome the resistance problem, and improve the drug efficacy is the direction of research by researchers in this field. Currently, there are no relevant reports on RC48-resistant cell lines for bladder cancer, construction methods, and their applications at home and abroad, nor are there any relevant studies on the resistance mechanism of RC48. Summary of the Invention
[0005] The present invention aims to solve the above problems. The first objective is to provide a disitamab vedotin-resistant cell line for human bladder cancer; the second objective is to provide a method for constructing the same; the third objective is to provide its related applications in bladder cancer research.
[0006] Specifically, the technical solutions adopted by the present invention are as follows:
[0007] In the first aspect of the present invention, a disitamab vedotin-resistant cell line for bladder cancer is provided. Using human bladder transitional cell carcinoma T24 cells as the induction object, a method of continuous induction with low concentration and gradually increasing the drug concentration and treatment time is adopted to induce and culture the cells for 5 months; the biological characteristics of the cells are evaluated through cell morphology observation, drug resistance detection, growth curve determination, flow cytometry detection of apoptosis, transcriptomics sequencing, and proteomics sequencing experiments, and a human bladder transitional cell carcinoma cell line resistant to RC48 is successfully constructed.
[0008] Specifically, this cell line is a human bladder transitional cell carcinoma RC48-resistant cell line, named human bladder cancer drug-resistant cell line T24-RC48 (Homo sapiens), which was deposited with the China Center for Type Culture Collection (CCTCC) on June 11, 2024, with the deposit number CCTCC NO: C2024180 and the deposit address: Wuhan University, Wuhan, China.
[0009] Preferably, after being stimulated by 393.7 μg / ml of RC48, this vidicitumumab-resistant cell line of bladder cancer can still stably grow and be passaged, which is the human bladder transitional cell carcinoma cell line T24; the drug resistance index to RC48 is 9.8. It can be applied to the research on the drug resistance mechanism of bladder cancer, etc.
[0010] In the second aspect of the present invention, a method for inducing and constructing the above-mentioned vidicitumumab-resistant cell line of bladder cancer is provided, including the following steps:
[0011] (1) Routinely culture the human bladder transitional cell carcinoma T24 cell line: Culture the human bladder transitional cell carcinoma T24 cell
[0012] line routinely in McCoy's 5A culture medium containing 10% fetal bovine serum and 1% double antibody (100 U / ml penicillin and 100 μg / ml streptomycin), and culture it in an incubator at 37°C and 5% CO2.
[0013] (2) Inoculate the T24 cell line into a multi-well plate cell culture flask (such as a 6-well plate cell culture flask), and change the culture medium after culturing for a certain
[0014] time (such as 24 hours); use the concentration gradient method (add RC48 at multiple concentration gradients respectively) to take the highest RC48 concentration as the initial IC50; change the fresh culture medium again, continue to culture the cells, determine the highest concentration that the cells can tolerate as the initial dosing concentration, and passage the cells treated at this concentration;
[0015] (3) Inoculate the T24 cells into a T25 cell culture flask, change the fresh culture medium after 24 hours, and add the initial
[0016] dosing concentration of RC48 for induction. After 24 hours, change the fresh culture medium, and continue to culture the cells until the cell saturation density is above 80%, and passage 1 time;
[0017] (4) Repeat the operation in step (3), gradually increase the RC48 induction concentration until the cells can survive and normally expand after being treated with 100 μg / ml of
[0018] RC48 for 24 hours;
[0019] (5) Inoculate T24 cells into a T25 cell culture flask. After 24 hours, replace the fresh culture medium and add
[0020] 100 μg / ml of RC48 for induction. After 48 hours, replace the fresh culture medium, and continue culturing the cells until the cell saturation density reaches more than 80%. Passage once.
[0021] (6) Repeat the operation in step (5), gradually increase the RC48 induction concentration. After 5 months of induction, obtain
[0022] The human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48 established by RC48 induction.
[0023] Cell morphological observation shows that compared with the T24 parental cells, T24-RC48 is overall smaller in size, shows aggregated growth, and has changed in morphology; the drug resistance index detection shows that the drug resistance index of T24-RC48 to RC48 is 9.8, and the sensitivity to RC48 is very low; in terms of growth rate, affected by RC48, T24-RC48 is significantly smaller than T24 cells; genetically, the genetic background and biological characteristics (genes and proteins) of T24-RC48 have both changed significantly.
[0024] Based on the above changes, the third aspect of the present invention provides the application of the vidicitumumab-resistant cell line of human bladder cancer. Such as the application in screening or developing drugs for treating bladder cancer or drugs for reversing bladder cancer drug resistance; the application in preparing a system for evaluating the anti-tumor activity of drugs or a system for evaluating the sensitivity of anti-tumor drugs.
[0025] Further preferably, using this resistant cell line can be constructed to provide resistant bladder cancer cells or animal models for the following related studies: studying the morphology and biological characteristics of resistant bladder cancer cells, studying the mechanism of bladder cancer drug resistance, evaluating the anti-tumor activity of drugs, preparing tumor cell models or tumor animal models, and screening and developing drugs for reversing bladder cancer drug resistance in vitro.
[0026] Specifically, the bladder cancer cell model is constructed by transfecting the above-mentioned vidicitumumab-resistant cell line of human bladder cancer or its progeny cells with a gene with a fluorescent label; the bladder cancer animal model is constructed by the method of subcutaneous tumor inoculation or tail vein injection of the vidicitumumab-resistant cell line of human bladder cancer.
[0027] Compared with the prior art, the present invention has the following advantages:
[0028] The construction method of the human bladder transitional cell carcinoma RC48-resistant cell line provided by the present invention uses a method of continuously inducing with a low concentration and gradually increasing the RC48 drug concentration and treatment time, effectively inducing the formation of RC48-resistant cells. At the same time, the construction method of the present invention is simple to operate and can effectively make up for the deficiencies of existing methods.
[0029] The human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48 constructed by the present invention is generally smaller in cell morphology, shows aggregated growth, and has a longer proliferation cycle compared with the parental cell T24; its sensitivity to RC48 is greatly reduced, and it can stably grow and be passaged in a culture system containing 393.7 μg / ml of RC48, and the drug resistance index to RC48 is 9.8. It can be used for the study of the drug resistance mechanism of bladder cancer, the evaluation of the anti-tumor activity of drugs, the preparation of tumor cell models or the preparation of tumor animal models, providing a cell research model for finding effective drugs and methods to reverse the drug resistance of bladder cancer, and having good application prospects. Description of the Drawings
[0030] Figure 1 Shows the morphology of the parental cell T24 (left) and the RC48-resistant cell T24-RC48 (right) under a light microscope.
[0031] Figure 2 Shows the detection results of the sensitivity and drug resistance of the parental cell T24 and the RC48-resistant cell T24-RC48 to RC48.
[0032] Figure 3 Shows the results of the growth curve determination.
[0033] Figure 4 Shows the results of the flow cytometry detection of cell apoptosis.
[0034] Figure 5 Shows the volcano plot of differential genes in the proteomics sequencing analysis of the parental cell T24 and the RC48-resistant cell T24-RC48.
[0035] Figure 6 Shows the volcano plot of differential genes in the transcriptomics sequencing analysis of the parental cell T24 and the RC48-resistant cell T24-RC48.
[0036] Figure 7 Shows the Venn diagram of differential genes in the combined analysis of the parental cell T24 and the RC48-resistant cell T24-RC48. Detailed Embodiments
[0037] The following examples and experimental examples further illustrate the present invention and should not be construed as limiting the present invention. The examples do not include a detailed description of traditional methods, such methods being well known to those of ordinary skill in the art and having been described in many publications.
[0038] Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to persons skilled in the art. In addition, any methods and materials similar or equivalent to those described may be applied to the present invention, and the preferred implementation methods and materials described in the specific implementation manners are for illustrative purposes only.
[0039] Example 1 Induction and establishment of drug-resistant bladder cancer cell lines
[0040] The steps for inducing and constructing the drug-resistant cell line T24-RC48 of human bladder transitional cell carcinoma RC48 are as follows:
[0041] (1) The human bladder transitional cell carcinoma T24 cell line was routinely cultured in McCoy's 5A culture medium containing 10% fetal bovine serum and 1% double antibody (100 U / ml penicillin, 100 μg / ml streptomycin) in an incubator at 37°C and 5% CO2.
[0042] (2) The T24 cells were inoculated into a 6-well cell culture flask. After 24 hours, the fresh culture medium was replaced, and RC48 at 6 concentration gradients was added respectively. The highest concentration was the initial IC50. After 24 hours, the fresh culture medium was replaced, and the cells were continuously cultured to determine the highest concentration that the cells could tolerate as the initial dosing concentration, and the cells treated at this concentration were passaged.
[0043] (3) The T24 cells were inoculated into a T25 cell culture flask. After 24 hours, the fresh culture medium was replaced, and RC48 at the initial dosing concentration was added for induction. After 24 hours, the fresh culture medium was replaced, and the cells were continuously cultured until the cell saturation density was above 80%, and then passaged once.
[0044] (4) The operation in step (3) was repeated, and the induction concentration of RC48 was gradually increased until the cells could survive and expand normally after being treated with 100 μg / ml of RC48 for 24 hours.
[0045] (5) The T24 cells were inoculated into a T25 cell culture flask. After 24 hours, the fresh culture medium was replaced, and 100 μg / ml of RC48 was added for induction. After 48 hours, the fresh culture medium was replaced, and the cells were continuously cultured until the cell saturation density was above 80%, and then passaged once.
[0046] (6) Repeat the operation in step (5), gradually increase the RC48 induction concentration. After 5 months of induction, the human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48 established by RC48 induction was obtained. This resistant cell line can stably grow and be passaged in a culture system containing 393.7 μg / ml of RC48, and the resistance index to RC48 is 9.8.
[0047] The obtained cell line was named human bladder cancer resistant cell line T24-RC48 (Homo sapiens), and was deposited in the China Center for Type Culture Collection (CCTCC) on June 11, 2024. The deposit number is CCTCC NO: C2024180, and the deposit address is: Wuhan University, Wuhan, China.
[0048] Example 2 Morphological observation of parental cells and resistant cell lines
[0049] 1. Experimental materials:
[0050] Human bladder transitional cell carcinoma T24 (parental cells), and the bladder cancer RC48-resistant cell line constructed in Example 1, namely human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48.
[0051] 2. Experimental methods:
[0052] Inoculate the logarithmic growth phase parental cells T24 and resistant cells T24-RC48 into six-well plates respectively. After 24 hours, observe the cell morphology under an inverted phase contrast microscope and take pictures.
[0053] 3. Experimental results:
[0054] The experimental results are as Figure 1 shown: T24 parental cells are adherent cells, and most cells show epithelial-like adherent growth under the microscope; compared with the parental cells, the RC48-resistant cells T24-RC48 are smaller in overall cell size and show aggregated growth in morphology. The above results indicate that the bladder cancer RC48-resistant cell line has changed in morphology.
[0055] Example 3 Determination of the resistance index of the RC48-resistant cell line
[0056] 1. Experimental materials:
[0057] Human bladder transitional cell carcinoma T24 (parental cells), and the bladder cancer RC48-resistant cell line constructed in Example 1, namely human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48.
[0058] 2. Experimental methods:
[0059] The logarithmic growth phase parental cells T24 and drug-resistant cells T24-RC48 were respectively counted and diluted into cell suspensions with a density of 4×10 4 cells / ml, and 100 μl of the cell suspension was inoculated into each well of a 96-well plate. The 96-well cell culture plate was placed in a cell culture incubator at 37 °C and 5% CO2. After the cells adhered, 100 μl of the prepared drug-containing medium solution with different concentrations of RC48 was added to each well (the RC48 concentration gradients for T24-RC48 were 1, 5, 10, 50, 100, 200, 300, 400, 500 μg / ml, and the RC48 concentration gradients for T24 were 1, 5, 10, 50, 100, 500 μg / ml), and 5 replicates were set for each concentration. After the cells were continuously cultured in the incubator for 72 h, 100 μl of the medium was carefully aspirated, 100 μl of the complete medium containing 10% CCK8 was added to each well, and the cells were continuously cultured at 37 °C for 1 h. The OD value of each well was detected using an enzyme-linked immunosorbent assay (ELISA) reader at 450 nm, the cell survival rate of each group was calculated, and the drug resistance index was calculated based on the RC48 cytotoxic IC50 value.
[0060] Cell survival rate (%) = (OD value of the experimental well - OD value of the blank well) / (OD value of the control well - OD value of the blank well) × 100%
[0061] Drug resistance index = IC50 of RC48 in drug-resistant cells / IC50 of RC48 in parental cells.
[0062] 3. Experimental results:
[0063] The experimental results are shown in Table 1 and Figure 2 as follows. The drug resistance index of the human bladder transitional cell carcinoma RC48 drug-resistant cell line T24-RC48 constructed in the present invention was 9.8 for RC48.
[0064] Table 1 Detection results of the drug resistance index of the human bladder transitional cell carcinoma RC48 drug-resistant cell line T24-RC48
[0065]
[0066] Example 4 Determination of growth curve
[0067] 1. Experimental materials:
[0068] Human bladder transitional cell carcinoma T24 (parental cells), and the bladder cancer RC48 drug-resistant cell line constructed in Example 1, namely the human bladder transitional cell carcinoma RC48 drug-resistant cell line T24-RC48.
[0069] 2. Experimental method:
[0070] After trypsinizing the parental cell line T24 and the RC48-resistant cell line T24-RC48, they were respectively inoculated into 6 96-well cell culture plates and numbered. Each cell line was inoculated into 12 wells, with 3×103 cells in each well. 100 μL of complete medium was added, and the plates were cultured in an incubator at 37°C and 5% CO2. After overnight incubation, 5 of the 96-well plates were taken to replace the fresh medium (200 μg / ml of RC48 was added to the fresh medium in 6 wells of each culture plate). The time at this point was recorded as 0, and the plates were continued to be cultured in an incubator at 37°C and 5% CO2. For the remaining plate (plate No. 1), according to the requirements of the CCK-8 kit instruction manual, the chromogenic solution was added to the culture wells, and the plates were continued to be cultured in the incubator for 1 h. The absorbance value at 450 nm was measured using a microplate reader. The absorbance values at 450 nm of culture plates No. 2-6 were measured using the same method every 24 h. With the RC48 treatment time as the abscissa and the absorbance value at 450 nm as the ordinate, a cell proliferation curve was plotted.
[0071] 3. Experimental results:
[0072] It can be seen from Figure 3 that there was no significant difference in the doubling time between the parental cell line T24 and the RC48-resistant cell line T24-RC48. After adding the drug, the doubling time of T24-RC48 was relatively prolonged compared with that without adding the drug, but it was still significantly shorter than that of the parental T24 cells after adding the drug. Thus, it can be seen that the growth rate of the cell line T24-RC48 disclosed in the present invention is significantly less affected by RC48 than the existing T24 cells.
[0073] Example 5 Flow cytometry detection of cell apoptosis
[0074] 1. Experimental materials:
[0075] Human bladder transitional cell carcinoma T24 (parental cell line), and the bladder cancer RC48-resistant cell line constructed in Example 1, namely the human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48.
[0076] 2. Experimental methods:
[0077] The parental cell line T24 and the RC48-resistant cell line T24-RC48 were respectively seeded into 6-well plates, with 2 wells for each cell line. After 24 h, the fresh medium was replaced (200 μg / ml of RC48 was added to the fresh medium in 1 well of each cell line). After 48 h, the medium was aspirated, and according to the requirements of the apoptosis kit, Accutase, Annexin V-FITC, PI, and Apoptosis Positive Control Solution were added to collect and process the cells. The cells were analyzed by flow cytometry, and the results were processed using the cell cycle analysis software Flowjo.
[0078] 3. Experimental results:
[0079] The detection results are as follows Figure 4 shown: Before adding the drug, the cells in early apoptosis of T24 accounted for 1.32%, and the cells in late apoptosis accounted for 6.34%. Before adding the drug, the cells in early apoptosis accounted for 9.19%, and the cells in late apoptosis accounted for 16.97%. Before adding the drug, the cells in early apoptosis of T24-RC48 accounted for 0.70%, and the cells in late apoptosis accounted for 5.09%. Before adding the drug, the cells in early apoptosis accounted for 0.96%, and the cells in late apoptosis accounted for 6.60%. It can be seen that compared with the existing T24 cells, the cell T24-RC48 disclosed in the present invention has a very low sensitivity to RC48.
[0080] Example 6 Analysis of Proteomic Differences between Drug-Resistant Cells and Parental Cells
[0081] 1. Experimental materials:
[0082] Human bladder transitional cell carcinoma T24 (parental cells), and the bladder cancer RC48 drug-resistant cell line constructed in Example 1, namely the human bladder transitional cell carcinoma RC48 drug-resistant cell line T24-RC48.
[0083] 2. Experimental method:
[0084] The parental cells T24 and drug-resistant cells T24-RC48 in the logarithmic growth phase were respectively inoculated into 10 cm culture dishes. When the cells grew to more than 80% in a cell culture incubator at 37°C and 5% CO2, the culture medium was discarded. Add pre-cooled PBS at 4°C, gently shake horizontally for 1 minute to wash the cells, and then discard the PBS. Repeat the washing twice to wash away the culture medium. Place the culture dish obliquely on ice. Add pre-cooled PBS at 4°C to the culture dish. Use a clean cell scraper to scrape the cells to one side of the bottom of the culture dish. Pipette the lysate into a pre-cooled centrifuge tube, centrifuge to remove the supernatant, and conduct Label-free quantitative proteomics research.
[0085] 3. Experimental results:
[0086] The results are as follows Figure 5Shown as follows: In this experiment, label-free quantitative proteomics technology was used for detection and analysis. A total of 4,988 proteins were identified in the parental cell line T24 and the drug-resistant cell line T24-RC48, among which 4,988 proteins were quantified. According to the criteria of a fold change in expression of more than 2.0 times (upregulation greater than 2.0 times or downregulation less than 0.50 times) and a P value < 0.05, significantly differentially expressed proteins were screened. The analysis results showed that compared with the parental cells, the expression levels of 479 proteins in the drug-resistant cell line T24-RC48 changed significantly, among which 177 proteins were significantly upregulated and 302 proteins were significantly downregulated. The above results indicate that compared with the parental cell line T24, the genetic background and biological characteristics of the drug-resistant cell line T24-RC48 have changed significantly.
[0087] Example 7 Transcriptomic Difference Analysis between Drug-Resistant Cells and Parental Cells
[0088] 1. Experimental Materials:
[0089] Human bladder transitional cell carcinoma T24 (parental cells), and the bladder cancer RC48 drug-resistant cell line constructed in Example 1, namely the human bladder transitional cell carcinoma RC48 drug-resistant cell line T24-RC48.
[0090] 2. Experimental Methods:
[0091] The parental cells T24 and the drug-resistant cells T24-RC48 in the logarithmic growth phase were respectively inoculated into 10 cm culture dishes. When the cells grew to more than 80% in a cell culture incubator at 37 °C and 5% CO2, the culture medium was discarded. The cells were quickly washed once with PBS buffer; for every 1 × 10 7 cells, 1 - 1.5 ml of TRIzol reagent was added; the cells were repeatedly pipetted with a 1 ml pipette tip to make the TRIzol contact the surface of all culture flasks with cells and were fully digested. The mixture was transferred to a 1.5 ml RNase-free centrifuge tube, and the cells were repeatedly pipetted until no cell clumps could be seen and the whole solution was clear and not viscous; after quick freezing in liquid nitrogen, it was stored in a -80 °C refrigerator for transcriptomic research.
[0092] 3. Experimental Results:
[0093] The results are as Figure 6 and Figure 7As shown: A total of 27,029 gene expressions were identified by transcriptomic sequencing in the parental cell line T24 and the drug-resistant cell line T24-RC48. Screening for significantly differentially expressed genes was performed according to the criteria of padj less than 0.05 and log2FoldChange greater than or equal to 1.0. The analysis results showed that compared with the parental cells, the expression levels of 2,059 genes in the T24-RC48 drug-resistant cell line changed significantly, among which the expression of 1,118 genes was significantly up-regulated and the expression of 941 genes was significantly down-regulated. This indicates that compared with the parental cell line T24, the genetic background and biological characteristics of the drug-resistant cell line T24-RC48 have changed significantly.
[0094] In the method for constructing the human bladder cancer RC48 drug-resistant cell line of the present invention, by continuously inducing with low concentrations and gradually increasing the drug concentration and treatment time, the formation of RC48 drug-resistant cells can be effectively induced. This method is simple to operate and can effectively make up for the deficiencies of existing methods. The bladder cancer RC48 drug-resistant cell line obtained by using the drug-resistant cell construction method of the present invention can be used for the study of the drug resistance mechanism of bladder cancer, the screening of anti-bladder cancer drugs, and provides a cell research model for finding effective drugs and methods to overcome bladder cancer drug resistance, and has good application prospects and important scientific significance.
[0095] The parts not described in the present invention are the same as or implemented by the prior art. The applicant declares that the present invention uses the above embodiments to illustrate the detailed method of the present invention, but the present invention is not limited to the above detailed method, that is, it does not mean that the present invention must rely on the above detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, the equivalent replacement of each raw material of the product of the present invention, the addition of auxiliary components, and the selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A bladder cancer vedicizumab-resistant cell line, characterized in that: The cell line is named as human bladder cancer resistant cell line T24-RC48, and its preservation number is: CCTCC NO: C2024180.
2. The bladder cancer vedicizumab-resistant cell line according to claim 1, characterized in that The bladder cancer vedicizumab-resistant cell line is a human bladder transitional cell carcinoma line T24 cell that can still stably grow and be passaged after being stimulated with 393.7 μg / ml of RC48.
3. The method for inducing and constructing a bladder cancer vedicizumab-resistant cell line according to claim 1 or 2, characterized in that: The steps include: (1) The human bladder transitional cell carcinoma T24 cell line was routinely cultured; (2) Inoculate the T24 cell line into a multi-well plate cell culture flask, replace the culture medium, and use the concentration gradient method to determine the highest RC48 concentration as the initial IC50; replace the culture medium again with fresh medium, continue to culture the cells, determine the highest concentration that the cells can tolerate as the initial dosing concentration, and pass the cells treated with this concentration; (3) Inoculate T24 cells into T25 cell culture flasks and replace with fresh culture medium after 24 hours. The cells were induced by injecting RC48 at the initial concentration, and fresh culture medium was replaced after 24 hours. The cells were cultured until the cell saturation density was above 80%, and the cells were passaged once. (4) Repeat step (3) and gradually increase the RC48 induction concentration until the cells can be grown at 100 μg / ml. RC48 survived and expanded normally after 24 hours of treatment; (5) Inoculate T24 cells into T25 cell culture flasks and replace with fresh culture medium after 24 hours. 100 μg / ml RC48 was added for induction, and fresh culture medium was replaced after 48 hours. The cells were cultured until the cell saturation density was above 80%, and the cells were passaged once; (6) Repeat step (5) and gradually increase the RC48 induction concentration. After 5 months of induction, The human bladder transitional cell carcinoma RC48-resistant cell line T24-RC48 induced by RC48 was obtained.
4. The method for inducing and constructing a bladder cancer vedicizumab-resistant cell line according to claim 3, characterized in that: In step (1), the method for routinely culturing the human bladder transitional cell carcinoma T24 cell line is as follows: the human bladder transitional cell carcinoma T24 cell line is routinely cultured in McCoy's 5A culture medium containing 10% fetal bovine serum and 1% double antibody, and cultured in a 37°C, 5% CO2 incubator, wherein the 1% double antibody consists of 100U / ml penicillin and 100μg / ml streptomycin.
5. The method for inducing and constructing a bladder cancer vedicizumab-resistant cell line according to claim 3, characterized in that: The resistance index of the obtained vedicizumab-resistant bladder cancer cell line to RC48 was 9.
8.
6. Use of the vedicizumab-resistant bladder cancer cell line according to claim 1 or 2 in screening or developing drugs for treating bladder cancer or drugs for reversing bladder cancer resistance.
7. Use of the vedicizumab-resistant bladder cancer cell line according to claim 1 or 2 in the preparation of a system for evaluating the anti-tumor activity of a drug or a system for evaluating the sensitivity of an anti-tumor drug.
8. Use of the bladder cancer vedicizumab-resistant cell line according to claim 1 or 2 in constructing a bladder cancer cell model or an animal model.
9. A bladder cancer cell model or animal model, characterized in that: The bladder cancer cell model is obtained by transfecting the bladder cancer vedicizumab-resistant cell line described in claim 1 or 2 or the progeny cells established therefrom with a fluorescently labeled gene; the bladder cancer animal model is obtained by modeling the bladder cancer vedicizumab-resistant cell line by subcutaneous tumor implantation or tail vein injection.
10. Use of the bladder cancer cell model or animal model according to claim 9 in studying the drug resistance mechanism of bladder cancer.
Citation Information
Cited By
Method for constructing RC48 acquired drug resistance in-situ gastric cancer mouse model and RC48 acquired drug resistance in-situ gastric cancer mouse model
CN121464984A
